Eris Lifesciences Limited (NSE: ERIS)

Market Cap	187.04B
Revenue (ttm)	24.85B
Net Income (ttm)	3.48B
Shares Out	136.11M
EPS (ttm)	25.58
PE Ratio	53.72
Forward PE	39.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,615
Open	1,376.95
Previous Close	1,366.90
Day's Range	1,361.65 - 1,395.50
52-Week Range	809.15 - 1,522.05
Beta	0.31
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 31, 2024

About Eris Lifesciences

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measureme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 3,620
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ERIS

Financial Performance

In 2023, Eris Lifesciences's revenue was 19.91 billion, an increase of 19.83% compared to the previous year's 16.62 billion. Earnings were 3.92 billion, an increase of 2.57%.